Role of betaine in improving the antidepressant effect of S-adenosyl-methionine in patients with mild-to-moderate depression
Authors Di Pierro F, Orsi R, Settembre R
Received 19 November 2014
Accepted for publication 11 December 2014
Published 16 January 2015 Volume 2015:8 Pages 39—45
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Francesco Di Pierro,1 Rossana Orsi,2 Roberto Settembre3
1Scientific Department, Velleja Research, Milan, Italy; 2ASL TO1, Turin, Italy; 3Neurosurgery Department, ASL BA, Di Venere Hospital, Bari, Italy
Background: S-adenosyl-methionine (SAMe) is a common add-on treatment used to counteract depressive symptoms in subjects with mild-to-moderate depression, who are low responders to other antidepressant drugs. However, there is some concern about the possible impact of SAMe therapy on homocysteine levels. Betaine is known both to counteract high level of homocysteine in plasma and to increase liquor and plasma levels of SAMe, thus potentiating its effect.
Aim: To evaluate the role played by betaine, administered along with SAMe, in potentiating the antidepressive role played by SAMe administered as such.
Methods: The study enrolled 46 subjects with a diagnosis of mild-to-moderate depression according to the Beck Depression Inventory Scale II. All the subjects had a suboptimal control of their symptoms. After randomization, they were treated with adjunctive treatment with either Samyr® (enteric-coated SAMe) or DDM Metile® (enteric-coated SAMe plus betaine) for 90 days.
Results: Both treatments acted similarly in improving symptoms such as anxiety, psychomotor agitation, feelings of helplessness and worthlessness, physical efficiency, and somatization, but treatment with DDM Metile® determined better statistically significant results following a 90-day therapy. Tolerability and compliance were overlapping in both the treatments.
Conclusion: The association of SAMe plus betaine seemed to demonstrate more effectiveness than SAMe alone when administered as an add-on therapy to subjects, affected by mild-to-moderate depression, who were low responders to conventional antidepressants.
Keywords: DDM Metile®, Samyr®, Betaine, SAMe, mild-to-moderate depression, methyl donor
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]